Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
about
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.Drug conjugates—an emerging approach to treat breast cancer.Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures
P2860
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bystander killing effect of DS ...... ctor receptor 2 heterogeneity.
@en
Bystander killing effect of DS ...... ctor receptor 2 heterogeneity.
@nl
type
label
Bystander killing effect of DS ...... ctor receptor 2 heterogeneity.
@en
Bystander killing effect of DS ...... ctor receptor 2 heterogeneity.
@nl
prefLabel
Bystander killing effect of DS ...... ctor receptor 2 heterogeneity.
@en
Bystander killing effect of DS ...... ctor receptor 2 heterogeneity.
@nl
P2093
P2860
P356
P1433
P1476
Bystander killing effect of DS ...... ctor receptor 2 heterogeneity.
@en
P2093
Hiroyuki Naito
Katsunobu Hagihara
Masataka Oitate
P2860
P304
P356
10.1111/CAS.12966
P577
2016-05-11T00:00:00Z